Intellectual disability is one of the most genetically heterogeneous human disorders. 1 Among these, X-chromosomelinked intellectual disability (XLID) has been the best characterized at >92 genes involved. 2 Recent large-scale X-exome resequencing 3 complemented by high-resolution copy-number profiling 4 failed to provide imminent answers for >50% of 208 families studied. Both studies used exome-centric and thus coding-sequence-biased mutation searches. Currently, about 86% of~100,000 known mutations causing human disease reside in the coding sequences. 5 Noncoding variants are frequently overlooked or deemed too hard to be investigated. However, the advent of more systematic whole-genome sequencing, 6 together with constantly improving annotation of the human genome (ENCODE), is facilitating mutation inquiry also into the noncoding and regulatory sequences. MRX3 is a family of northern European descent and is affected by nonsyndromic intellectual disability (MIM 309541), which was mapped to Xq28-qter in 1991. 7 The affected males in the MRX3 family are generally facially nondysmorphic; a few of the males have been described as having subtle dysmorphism, such as a small chin, high arched palate, or tapered fingers, but no feature is consistent throughout the family. Body habitus is normal and consists of below-average height (<3 rd to 25 th percentile) and a head shape that is often brachycephalic and of variable size (5 th to 97 th percentile). Affected males function within a variable range, from mild to moderate intellectual disability. Some males live semi-independently with supervised employment, whereas others need fulltime supervision. Many of the males show behavioral problems, including aggression, and are not easily managed. In addition, others are described as reclusive and display a number of autistic symptoms, including ritualized and obsessive behaviors, narrow interests, and little socialization. Only one of the affected males (V-14 in Figure S1 , available online; now deceased) has been described as having psychotic symptoms. One male (VII-7 in Figure S1 ), who had absence seizures during childhood, has normal cerebral imaging. No other affected males have epilepsy or have had brain imaging. Obligate carrier females appear to be normal and show high (>96%) skewing of their X inactivation, as measured on white blood cells (data not shown). This study was approved by the Women's and Children's Health Network Human Research Ethics Committee, and informed consent was obtained from all participants. The 5.6 Mb linkage interval of the MRX3 family is known to be rich in genes 8 and harbors 108 protein-coding genes ( Figure 1A ), accounting for~2.42% of the whole sequence in the interval. For over 20 years, extensive studies, including the most recent large-scale approaches, 3, 4 have failed to identify the causative mutation.
In the presence of solid genetic evidence for X chromosome involvement, we hypothesized that the mutation might reside outside the coding region. To identify potential noncoding variants, we designed a custom capture array targeted to all coding regions and putative functional noncoding regions in the linkage interval ( Figure 1A ). Genomic DNA from individual V-4 in the MRX3 family 7 was enriched to an estimated mean of 1,4163 ( Figure S1 and data not shown). The captured DNA fragments were sequenced with the Illumina GAIIx massively parallel sequencing platform, and 4.78 3 10 6 65 bp reads (51.64%
of the total number of reads) mapped to a repeat-masked, human genome reference sequence from UCSC (hg18) as described previously 9 and covered 1.29 3 10 6 bp of unique sequences in the linkage interval ( Figures S2 and S3 ). Combined with our previous X-exome Sanger sequencing data, 3 only 356 bp (<0.25% of the coding region from the linkage interval) distributed over four genes showed zero coverage (Tables S1 and S2 ). These zerocoverage coding regions (which included the first exon of SLC6A8 [MIM 300036], a gene which has been shown to be mutated in XLID) were sequenced manually and were excluded from having DNA sequence variation in the MRX3 family. In total, 383 genetic variants were called. We prioritized variants not present in dbSNP130 for further analysis ( Figure S3 (Figures 1B-1D) . A recent study reported a de novo YY1 (MIM 600013) mutation as a plausible cause of intellectual disability. 10 With TFSEARCH, 11 the variant was predicted to abolish YY1
binding. Other variants were weakly conserved or poorly annotated and were not investigated for functional effect(s). There are six YY1 binding sites (S1-S6) in the same orientation in the region between HCFC1 and TMEM187 12 ( Figure 1D ). We postulated that HCFC1 is the most likely affected gene. The S2 chrX:152,890,455A>G variant completely segregated with intellectual disability in the original and extended MRX3 pedigrees ( Figure S1 ). According to the HCFC1 reference sequence, NM_005334.2, the S2 chrX:152,890,455A>G variant would be in the intergenic region. However, our analysis of human expressed sequence tags (ESTs) and other publicly available resources (e.g., ENCODE and DBTSS) strongly suggests that the predominant HCFC1 transcription start site (TSS) is 450 bp upstream of NM_005334.2 at chrX: 152,890,463 (see Figure 2D ) This makes the chrX:152,890,455A>G variant (and the S2 YY1 binding site) part of the HCFC1 5 0 UTR, only~8 bp from the TSS of HCFC1 ( Figures 1D and 2D ).
To assess the impact of the S2 chrX:152,890,455A>G variant on HCFC1 expression, we tested the relative levels of total HCFC1 transcripts by using quantitative RT-PCR (qRT-PCR). The HCFC1 mRNA expression in affected individuals' (n ¼ 2) lymphoblastoid cell lines (LCLs) was >1.63 higher (p < 0.006, Student's one-tailed t test) than that in male and female controls ( Figure 2A and Figures S4-S6 ). Given that HCFC1 is duplicated in the majority of individuals with MECP2 (MIM 300005) duplications, we also tested HCFC1 expression in cell lines of these affected individuals ( Figure 2A and data not shown). No significant difference in HCFC1 expression was identified, suggesting that HCFC1 is not upregulated when duplicated. This also suggested to us that the YY1 binding site at position S2 is a repressive cis-regulator rather than an enhancer. 12 We also tested the possibility that S2
could function as a remote cis-regulatory sequence for neighboring genes, namely TMEM187 and, more distantly, RENBP (MIM 312420) 20 and MECP2. 21 The expression of TMEM187 is highly variable and not responsive to S2 variation in the affected individuals from the MRX3 family. Although RENBP expression is significantly (2-fold) upregulated in individuals with MECP2 duplications, it is only slightly upregulated in the affected individuals from the MRX3 family. MECP2 expression is higher in the affected individuals from the MRX3 family, but this was not statistically significant ( Figure 2A and Figure S4 ). We therefore concluded that HCFC1 is likely to be the only gene significantly affected by the S2 chrX:152,890,455A>G variant in the YY1 binding site. To further investigate whether the chrX: 152,890,455A>G variant has a functional effect, we performed an electrophoretic mobility shift assay (EMSA) by using the nuclear extracts from human embryonic kidney (HEK) 293T cells. The presence of the variant completely abolished YY1 binding ( Figure 2B ). This was supported by chromatin immunoprecipitation with a YY1 antibody in LCLs from affected individuals from the MRX3 family ( Figure 2C ). To study the effect of the S2 YY1 binding site on HCFC1 expression and explore the activity of the other neighboring YY1 binding sites, we generated wild-type and mutant S2 luciferase reporter constructs with different lengths of the HCFC1 and TMEM187 UTRs and intergenic regions ( Figure 2D ). The construct containing S1, S2, and S3 was the only one significantly impacted by the S2 chrX:152,890,455A>G variant ( Figure 2D ).
That HCFC1 is highly expressed during embryonic brain development 20 ( Figure S7 ) led us to investigate the effect that HCFC1 overexpression has on the behavior of embryonic murine neural cells, namely neural stem cells (NSCs) and embryonic hippocampal neurons. We employed nucleofection to deliver expression plasmids encoding enhanced green fluorescent protein (EGFP) and either an empty-vector control or a HCFC1 expression plasmid into ex-vivo cultures of these neural populations, resulting in cotransfection of 30%-40% of cells (data not shown). In NSCs grown nonadherently (i.e., as neurospheres), overexpression of HCFC1 slightly reduced the proliferation of the entire culture ( Figure 3A) . To resolve further, we used the 5-ethynyl-2 0 -deoxyuridine (EdU) pulse label assay to identify cells in S phase (i.e., proliferative cells). To restrict analysis to only transfected cells (i.e., those expressing EGFP), we employed either fluorescent-activated cell sorting (FACS) or immunofluorescent microscopy. Overexpression of HCFC1 resulted in a significant reduction in the percentage of EdU-labeled cells (~11% lower than controls) grown nonadherently ( Figure 3B ), whereas under adherent culture conditions more permissive to differentiation, the percentage of EdU-labeled cells was even further reduced (~28% lower than controls) ( Figure 3C and Figure S8 ). Because analysis of the cell-cycle length revealed no significant difference ( Figure 3D ), we explored the possibility that HCFC1 overexpression might instead promote cellcycle exit. We used immunofluorescent microscopy to quantify the differentiation status of transfected cells. The overexpression of HCFC1 significantly increased the production of astrocytes (~30% higher than controls), whereas the percentages of neurons and oligodendrocytes were unaffected (Figures 3E and 3F and Figure S8 ). Next, Relative expression normalized against the ACTB mRNA is shown for HCFC1, MECP2, and YY1. qRT-PCR was performed as previously described 13 with primers listed in Table S4 . Error bars represent 5 standard error of the mean (SEM). (B) An electrophoretic mobility shift assay (EMSA) shows that the chrX:152,890,455A>G variant of S2 (mS2) abolishes YY1 binding. IgG is the unrelated rabbit IgG. Unlabelled probes are 253, 1003, and 5003 higher than labeled probes. The positions of the YY1 shift and YY1 supershift (antibody from Santa Cruz; sc-7341X) are indicated by arrows. Isolation of nuclear extracts and EMSA was performed as previously described 14, 15 with oligonucleotide probes listed in Table S5 . (C) The chrX:152,890,455A>G variant abolishes YY1 binding. A ChIP assay was performed on formaldehyde crosslinked LCL lysates from normal (WT; n ¼ 2) and MRX3 (MT; n ¼ 2) males with the use of rabbit anti-YY1 antibody or control IgG as previously described. 16 The level of YY1 binding to the S2 region of HCFC1 was determined by semiquantitative PCR. The S6 YY1 binding site and an unrelated region of DNA around HUWE1 were used as negative controls. All primers are listed in Table S6 . Whereas the region of S2 YY1 binding site shows a clear decrease of PCR product in the MRX3 males with respect to controls, this is not seen for a more distant S6 YY1 binding site PCR. A decrease rather than a complete loss of S2 PCR products in the MRX3 male LCL lysates is most likely due to immunoprecipitation of closely located YY1 binding sites (e.g., S1 and S3) rather than through the S2 site itself. Inputs (lanes [9] [10] [11] [12] Table S7 and were cloned into pGEMT (Promega). The 506 bp (chrX: 152,890,153-152,890,658) and 127 bp (chrX: 152,890,153-152,890,279) fragments were obtained with restriction-enzyme digests with XhoI and HindIII (for the 506 bp fragment) and AvrII and HindIII (for the 127 bp fragment) from pGEMT containing 705 bp inserts. All fragments were subsequently cloned into the multiple cloning site of the pGL4.1 luciferase reporter (Promega). The arrows show the direction of transcription. The right panel shows the results of the corresponding luciferase reporter assays conducted in HEK 293T cells as previously described. 14 Values are normalized against the 705 bp wild-type construct. Error bars represent standard deviation of at least three independent experiments. *p < 0.0007 by Student's t test. (E) Schematic of HCFC1 domain structure with the 53 Kelch domain region, the basic region (containing SIN3A 17 and ZBTB17 18 protein interacting regions), HCF1 repeats, and the acidic region. The two unique variants identified as part of this study are underlined. The two variants identified by Piton et al. 19 are indicated by an asterisk (*), and those identified by Tarpey et al. 3 are indicated by a number sign (#). The values in brackets are PolyPhen 2 scores. The diagram is not drawn to scale.
we addressed the effect of HCFC1 overexpression on the outgrowth of freshly isolated embryonic hippocampal neurons. HCFC1 overexpression resulted in a significant reduction in neurite growth as evidenced by a greater than 50% reduction in primary axon growth at day 4 of culture and a 33% reduction at day 8 ( Figures 3G and  3H ). This result was coupled with reductions in the degree of neurite arborization, as reported by the number of both axonal and dendritic termini, and high amounts of neuronal death ( Figure S9 ). Together, these data strongly 0 -deoxyuridine (EdU) labeling and detection were done with the Click-it EdU AlexaFluor647-Azide kits (Invitrogen) as per the manufacturer's instructions. In (B), EdU pulse labeling (6 hr) of transfected NSCs in nonadherent culture was analyzed with FACS (FACS AriaII flow cytometer, BD Bioscience), and in (C), 12 hr pulse labeling of transfected NSCs after 3 days of adherent culture was analyzed by immunofluorescent microscopy. (D) HCFC1 overexpression does not alter the length of the NSC cycle. NSCs were synchronized in S phase with hydroxyurea (HU) and were allowed to re-enter the cell cycle at the G2 phase in the presence of EdU, as previously described. 24 Cell-cycle length is inferred by the number of transfected cells that have transitioned through G2, M, G1, and back into S, which is reported by the number of cells labeled by EdU at 0, 8, and 24 hr as previously described. 24 (E-F) HCFC1 overexpression promotes differentiation of NSCs. In (E) are representative immunofluorescent images after 3 days of adherent culture. Transfected cells were identified via EGFP expression (green), and their differentiation status was obtained with antibodies against cell-type-specific marker proteins: GFAP was used for astrocytes (red), and CNPase was used for oligodendrocytes (cyan). Nuclei were stained with DAPI (blue). The upper-panel arrowheads indicate unidentified transfected cells, and the lower-panel arrowheads indicate transfected cells of astrocyte identity. The quantification of cellular identities is shown in (F). At least 300 cells were counted for each experiment (conducted in triplicate). (G-H) HCFC1 overexpression reduces primary axonal outgrowth in hippocampal neurons. In (G) is a representative immunofluorescent image of 4-day-old cultures. Transfected neurons were identified with GFP expression (green) and stained with antibodies specific for axons (Tau1; cyan) and dendrites (MAP2; red). Nuclei were stained with DAPI (blue). In (H) is the quantification of primary axonal length at days 4 and 8 of culture, conducted as previously described. 23 All staining and microscopy were conducted as previously described. 23, 25 suggest that HCFC1 is a potent regulator of embryonic neural development. Overexpression in NSCs promoted cell-cycle exit coupled with astrocyte production, whereas in neurons, overexpression hindered neurite growth and viability. The expression of the evolutionarily conserved transcription regulator HCFC1 is tightly regulated by YY1, which suggested to us that this is necessary to ensure that HCFC1 target genes are also strictly regulated. To investigate this further, we performed microarray expression profiling by using MRX3 (n ¼ 2) and control male (n ¼ 4) and female (n ¼ 5) LCLs on HT-12v4 (WGDASL) arrays (Illumina) (the NCBI Gene Expression Omnibus accession number for array data is GSE39326).
Background-subtracted expression values were quantile normalized with the lumi package from bioconductor. 26 Significant differential expression on probes with a detection threshold > 0 was determined with the limma package from bioconductor. 27 We identified 218 significantly de- . With the exception of LSG1, all these genes are involved in mitochondrial function or biogenesis, a process in which HCFC1 has been previously implicated. 29 Further analysis of the 218 genes identified a cluster of 24 genes whose products localize to mitochondria and show significant enrichment in this data set (p ¼ 0.0012 with medium classification stringency on DAVID 30 ). Significant enrichment was also noted for genes and their acetylation-involved proteins, which included those that bind to or directly acetylate histones, consistent with the known function of HCFC1 as a chromatin-associated transcriptional regulator. Overall, the array results support HCFC1 upregulation due to a mutation in the YY1 binding site as having an impact on downstream regulation of gene expression. The biological processes associated with known functions of HCFC1, together with the neural functions reported in this study, rank highly on functional-annotation tables of differentially expressed genes (Tables S8-S10) . Finally, we identified two additional unique HCFC1 variants by using systematic X chromosome exome sequencing of probands from unresolved families affected by X-chromosome-linked or X-chromosome-suggestive intellectual disability (Figures S10-S12 and Table S11 ; unpublished data). These include c.674G>A (p.Ser225Asn) (RefSeq accession number NM_005334.2) within one of the Kelch domains and c.5267C>T (p.Ala1756Val) (RefSeq NM_005334.2). We have also found a c.2626G>A (p.Gly876Ser) variant, which lies within the ZBTB17/ GABP2 binding domain of HCFC1 and has been identified in a frequency of 1/1,207 chromosomes (or 7/8,454; National Heart, Lung, and Blood Institute [NHLBI] Exome Variant Server). Variant p.Ser225Asn segregated in family D144 ( Figure S11 and Table S11), and variant p.Ala1756Val, as well as missense change c.356A>G (p.Gln119Arg) (RefSeq NM_005096.3) in another gene, ZMYM3 (MIM 300061), was found in the index affected individual of a family with four affected males in two generations (family D82, Table S11 ) but could not be tested for cosegregation with XLID because DNA from other family members was unavailable. The c.2626G>A (p.Gly876Ser) variant was found in a simplex case who had intellectual disability and whose mother had 100% skewing of X inactivation (family D147; Table S11 ). The X-exome sequencing of the affected individual from family D147 also identified a potentially deleterious change (c. 19 and data not shown), their functional effect has not been tested. All six amino acid positions are highly conserved across multiple species ( Figure S10 ). All together, the combined data strongly suggest that mutations of HCFC1 lead to different neurological phenotypes, which include but are not restricted to intellectual disability. There are several lines of evidence that implicate HCFC1 in biological processes important for normal neuronal function and development. HCFC1 was first identified as a crucial VP-16/Oct-1-interacting cell-proliferation factor involved in herpes simplex virus infection (for review, see Wysocka and Herr 32 The role of HCFC1 in neuronal cells is yet to be understood despite its high expression during embryonic brain development. 20, 40 We investigated HCFC1 overexpression, as observed in affected individuals from the MRX3 family, in embryonic neural cell types. In NSCs, overexpression resulted in cell-cycle exit coupled with the production of astrocytes. As implicated by others, our finding identifies HCFC1 as a regulator of stem cell behavior. 28, 41, 42 Studies of HCFC1 in cell-cycle regulation have revealed requirements during M-phase 43 and G0/G1-S phase progression. 17, 44 In static cell-culture models, HCFC1 is known to promote S-phase initiation; 17 however, evidence has also suggested that mutated HCFC1 can promote G0/G1 arrest. For example, during G0/G1, HCFC1 is known to occupy and repress promoters of S-phase genes by bridging interactions between the E2F4 (encoded by E2F4 [MIM 600659]) transcription factor and the Sin3 histone deacetylase, thus inhibiting S-phase initiation. 17 HCFC1 is also a key transcriptional coactivator of the retinoblastoma protein (Rb, encoded by Rb1 [MIM 614041]), a potent inhibitor of S-phase genes. 45 During muscle cell differentiation, this regulation is required for the cell-cycle exit of myoblasts and terminal differentiation into myotubes. 45 Finally, loss-of-function studies of the HCFC1 antagonist PDCD2 46 (encoded by PDCD2 [MIM 600866]) implicate HCFC1 activity as a negative regulator of embryonic stem cell maintenance. 42 The above evidence suggests that the effect that HCFC1 has on the cell cycle is likely to be dependent on the cellular context; this is consistent with its ability to interact with multiple transcription factors and opposing histone modifiers in a pleiotropic manner. We extended our studies beyond the roles of HCFC1 in NSCs to include postmitotic hippocampal neurons. Neurons overexpressing HCFC1 displayed significant reductions in neurite growth and viability. The reduction in viability might be a result of increased apoptosis. Deregulation of the complex containing HCFC1, the MLL histone methyltransferase, and E2F1 (encoded by E2F1 [MIM 189971]), which normally governs the transition from the G1-S phase of the cell cycle, is known to cause both DNA damage and orchestrate an ensuing apoptotic process. 47 Alternatively, other cellular insults mediated by global deregulation of gene expression might affect neuronal cell viability. For example, consistent with ChIP studies, 28 our microarray studies using cell lines from affected MRX3 family members identify mitochondrial function, which is known to impact neuronal viability, as a prominent process regulated by HCFC1. Massively parallel sequencing is revolutionizing the annotation of human DNA variation and thus leads to a dramatic shift in the understanding of the genetic architecture of human traits and heritable disorders in particular. Although the recent successes are heavily biased toward the discovery of disease-associated variation in coding exonic regions of the human genome, 5 our work demonstrates that mutations outside these regions can and should also be tackled.
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